Google
MDXH — MDXHEALTH SA ADR (Healthcare >> Diagnostics & Research)
MDXH FAQ
What is MDXH's ROE?
MDXHEALTH SA ADR reports a Return on Equity (ROE) of 437.67%.
What is MDXH's dividend yield?
MDXHEALTH SA ADR offers a dividend yield of 0.00%.
What is MDXH's Deepscope Quality Score?
Deepscope rates MDXH's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MDXH?
Deepscope's AI Timing Score for MDXH is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MDXH belong to?
MDXHEALTH SA ADR is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange.
|
USD 0.60
Price
-0.00
(-0.56%)
Day Change
|
|
|---|
MDXH, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.60 |
| PBV / Sector |
-2.72 / -24.29
|
| Earning Per Share | -0.96 |
| PE / Sector |
N/A / 37.70
|
| PEG or PE/Growth / Sector |
N/A / 1.35
|
| Average 1M Daily Value |
1.27 M
GREAT
|
| Average 1W Daily Value |
0.67 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-05 09:12:04 |
| Symbol | MDXH |
| Name | MDXHEALTH SA ADR |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 51.36 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 32.93 / 31,702.25 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: CAP Business Center, Herstal, Belgium, 4040
Phone: 866 259 5644
Website: https://mdxhealth.com
Employees: 364
Description: MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
